ProBioGen has appointed Dr. Alfred Merz, PhD, as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Merz previously served as Chief Operating Officer (COO) and interim CEO.

His expertise will be instrumental in driving the company’s next growth phase while solidifying ProBioGen’s position as a trusted partner in biopharmaceutical development and manufacturing for clinical and commercial supply, recognized for its scientific acumen, client-oriented flexibility, and reliability.

Dr. Merz joined ProBioGen in 2024 from Bayer Pharmaceuticals, where he served as Senior Vice President and Head of Product Supply Medical Devices. With over 30 years of international experience in manufacturing, operational excellence, and strategy development, Dr. Merz has worked for leading pharmaceutical and biotech companies, including Bayer and Novartis. 

“Alfred embodies impressive leadership and business acumen,” stated Dr. Wafik Bardissi, Chairman of ProBioGen’s Supervisory Board and CEO of Minapharm Pharmaceuticals SAE. “His strategic expertise is vital to accelerating ProBioGen’s growth, advancing therapeutic innovation globally through proprietary technologies, and fostering impactful partnerships while enhancing operational excellence.”